Notification & Public Disclosure of a Transaction

RNS Number : 9035V

Oncimmune Holdings PLC

26 July 2018

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notification and Public Disclosure of a Transaction

Nottingham, UK - 26 July 2018: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announces that on 25 July 2018, share options over 47,883 £0.01 ordinary shares of the Company were awarded to a consultant under the Company's USA Incentive Stock Option Plan.

Position	Number of Share Options Awarded	Exercise price per Share	Percentage of issued ordinary share capital
Consultant	47,883	£1.225	0.07%

The options are subject to the USA Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 25 July 2019 and each year thereafter for a further four years. All these options are exercisable at £1.225 pence, being the mid-market price of the Company's ordinary shares at the close of day on 25 July 2018.

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Giles Balleny

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Berenberg (Joint Broker)

Toby Flaux, Charlotte Sutcliffe

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 155,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK, Europe & Asia. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT®-Liver launched in May 2018 and further tests are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com

 

END

 

 

MSCRFMBTMBJTBBP